BTI
ABCL icon

Blue Trust Inc’s AbCellera Biologics ABCL Stock Holding History

Blue Trust Inc’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,168
Closed -$12K – 1985
2023
Q1 		$12K Sell
1,168
-99
-8% -$899 ﹤0.01% 1531
2022
Q4 		$13K Sell
1,267
-762
-38% -$8.8K ﹤0.01% 1433
2022
Q3 		$22K Buy
+2,029
New +$22.3K ﹤0.01% 1049

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Blue Trust Inc's ABCL Position: Q2 2023 in Review

Blue Trust Inc sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 1,168 shares — an estimated $12K sold.

Blue Trust Inc first reported a position in ABCL in Q3 2022 and held it in 3 quarters. The position peaked at $22K in Q3 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Blue Trust Inc reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Blue Trust Inc sold 1,168 AbCellera Biologics shares in Q2 2023, an estimated $12K.
  • Blue Trust Inc first reported a position in AbCellera Biologics in Q3 2022 and held it in 3 quarters.
  • Blue Trust Inc's AbCellera Biologics position peaked at $22K in Q3 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Blue Trust Inc's 13F filing for Q2 2023, filed 14 Jul 2023.